RNDO-564-001 trial: what clinicians have said so far
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
- NCT07218003 ↗
- Enrolling by invitation
- Rondo Therapeutics
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on RNDO-564-001 (RNDO-564; RNDO-564 plus pembrolizumab) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RNDO-564-001 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Multicenter, Phase 1/1b Study of RNDO-564 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Relapsed/Refractory Locally Advanced or Metastatic Urothelial Cancer and Other Solid Tumors Associated With Nectin-4 Expression
- Phase
- Phase 1
- Status
- Enrolling by invitation
- Conditions
- Non Small Cell Lung Cancer; Cervical Cancer; Head and Neck Squamous Cell Cancer; Triple Negative Breast Cancer (TNBC); Urothelial Carcinoma Bladder; Gastroesophageal Junction (GEJ) Adenocarcinoma; Esophageal Squamous Cell Cancer; Gastric Cancer; Cancer; Solid Tumors (Phase 1)
- Interventions
- RNDO-564; Pembrolizumab
- Arms
- Single Agent Dose Level 1 · Experimental
- Single Agent Dose Level 2 · Experimental
- Single Agent Dose Level 3 · Experimental
- Single Agent Dose Level 4 · Experimental
- Single Agent Dose Level 5 · Experimental
- Single Agent Dose Level 6 · Experimental
- Single Agent Dose Level 7 · Experimental
- Single Agent Dose Level 8 · Experimental
- Single Agent Dose Level 9 · Experimental
- Combination Dose Escalation- Dose Level 1 · Experimental
- Combination Dose Escalation - Dose Level 2 · Experimental
- Single Agent Dose Optimization - Dose Level 1 · Experimental
- Single Agent Dose Optimization - Dose Level 2 · Experimental
- Combination Dose Optimization - Dose Level 1 · Experimental
- Combination Dose Optimization- Dose Level 2 · Experimental
- Enrollment
- 149 (estimated)
- Primary outcomes
- All Arms: - Proportion of participants with adverse events (including dose limiting toxicities) as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0
- Dose Optimization Arms: • Identify one or more recommended Phase 2 doses (RP2D)
- Sponsor
- Rondo Therapeutics
- Start
- Nov 17, 2025
- Primary completion
- Feb 28, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07218003 · updated Jun 11, 2026